Scott M. Rocklage, Ph.D. Joins 5AM Ventures

Biotech Veteran and Former CEO of Cubist Pharmaceuticals Brings Additional

Senior Operating and Company Building Experience to 5AM Venture's Investment

Team



Oct 16, 2003, 01:00 ET from 5AM Ventures

    MENLO PARK, Calif., Oct. 16 /PRNewswire/ -- 5AM Ventures, a seed and
 early-stage venture capital firm focused on creating and building
 biotechnology companies, today announced that Scott M. Rocklage, Ph.D. has
 joined the firm as a Venture Partner.  Since 1994, Rocklage was CEO of Cubist
 Pharmaceuticals, Inc. and oversaw the development and FDA approval of Cubicin,
 as a new antibiotic treatment.  Prior to Cubist, Dr. Rocklage oversaw the
 development of two other FDA-approved pharmaceutical products as CEO of
 Nycomed Salutar, Inc.
     Rocklage joins the initial 5AM Ventures team of three investment
 professionals (John Diekman, Andy Schwab and Carin Mueller) who founded 5AM
 Ventures as a spin-out of Bay City Capital in June 2002.  During the first
 year, 5AM Ventures made investments in the following six biotechnology
 companies:  Alexza, Ambrx, Celscia Therapeutics, Kalypsys, Miikana
 Therapeutics and Symyx Therapeutics.
     "Scott is a wonderful addition to our early stage investment team,"
 commented John Diekman, PhD, founder and Managing Partner of 5AM Ventures.
 "He has successfully directed the approval of three U.S. NDAs, established
 strong development pipelines and built infrastructure for drug launches.
 Scott's successful operational experience will add significant value to our
 existing and future companies.  He has already become Executive Chairman of
 Miikana Therapeutics and we are close to finalizing another similar role in
 another portfolio company."
     Dr. Rocklage has known the 5AM founders for more than 15 years.  "I am
 very excited to be joining such an accomplished team of investors and
 entrepreneurs and I am looking forward to contributing my own experience to
 the growth of 5AM's portfolio of innovative and inspiring biotechnology
 ventures," said Rocklage.
     Dr. Rocklage is currently Chairman of Cubist, a NASDAQ-listed company,
 where he was Chief Executive Officer and a Director for nine years, from 1994
 to 2003.  Dr. Rocklage was President and CEO of Nycomed Salutar, Inc., a
 diagnostic imaging company, from 1990 to 1994, and President, CEO and Chairman
 of Nycomed Interventional, Inc., a medical device company, from 1992 to 1994.
 Previously he held various R&D positions at Salutar, Inc. and served in a
 number of research leadership functions at Catalytica, Inc.
     Dr. Rocklage has led teams that have raised over $500 million, including
 Cubist Pharmaceutical's initial public offering and many successful follow-on
 financings.  Dr. Rocklage is also a director of MDS Proteomics Inc. and
 Miikana Therapeutics and a board member of the Massachusetts Biotechnology
 Council and the BIO Emerging Company Section.  He is a member of the board of
 affiliates of the Whitehead Institute.  Dr. Rocklage received his B.S. in
 chemistry from the University of California, Berkeley and his Ph.D. in
 chemistry from the Massachusetts Institute of Technology.
 
     About 5AM Ventures
     5AM Ventures is a seed and early-stage fund focused on creating and
 building biotechnology companies.  The fund is sponsored by Bay City Capital
 (www.baycitycapital.com) and Versant Ventures (www.versantventures.com), two
 of the leading life science investment firms with over $1 billion under
 management.  For more information, visit www.5AMventures.com.
 
 

SOURCE 5AM Ventures